| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/20/2009 | CA2444116C Pharmaceutical dosage form of amorphous nelfinavir mesylate |
| 01/20/2009 | CA2423020C Use of antiprogestins for the induction of apoptosis in a cell |
| 01/20/2009 | CA2415438C .alpha. crystalline form of perindopril tert-butylamine salt |
| 01/20/2009 | CA2396678C Peptide derivatives and their pharmaceutically acceptable salts, processes for preparation of both, and use thereof |
| 01/20/2009 | CA2383916C Dispersion formulations containing lipase inhibitors |
| 01/20/2009 | CA2376676C Respiratory syncytial virus replication inhibitors |
| 01/20/2009 | CA2373484C Use of 1,4-benzothiazepine derivatives as drugs for overcoming resistance to anticancer drugs |
| 01/20/2009 | CA2372836C Substituted pyrrolidines as cell adhesion inhibitors |
| 01/20/2009 | CA2365240C Regulation of phospholipase d activity |
| 01/20/2009 | CA2352389C An oral formulation for gastrointestinal drug delivery |
| 01/20/2009 | CA2339961C Isoquinoline derivatives with angiogenesis inhibiting activity |
| 01/20/2009 | CA2338794C New oral formulation for 5-ht4 agonists or antagonists |
| 01/20/2009 | CA2337770C Amide derivatives which are useful as cytokine inhibitors |
| 01/20/2009 | CA2325633C Steroidal sapogenins and their derivatives for treating alzheimer's disease |
| 01/20/2009 | CA2322204C 5-aminoindeno(1,2-c)pyrazol-4-ones as anti-cancer and anti-proliferative agents |
| 01/20/2009 | CA2261040C Pharmaceutical composition comprising combination useful for treatment or prevention of arteriosclerosis or xanthoma |
| 01/20/2009 | CA2214531C Treatment of cytokine growth factor caused disorders |
| 01/15/2009 | WO2009009059A1 Spiro compounds as antagonists of tgf-beta |
| 01/15/2009 | WO2009008508A1 Antitumor agent comprising sulfostin and sulfostin-related compound as the active ingredient |
| 01/15/2009 | WO2009008461A1 Pharmaceutical composition for disease caused by proliferation of sex hormone sensitive cell |
| 01/15/2009 | WO2009008371A1 Di(arylamino)aryl compound |
| 01/15/2009 | WO2009008318A1 Electrolytically reduced water, hot water for bathing, and method for suppression of lumpy fat |
| 01/15/2009 | WO2009008120A1 Agent and method for stabilizing membrane protein |
| 01/15/2009 | WO2009006773A1 AN OPTICALLY ACTIVE N- (α-MERCAPTOPROPIONY) GLYCINE |
| 01/15/2009 | WO2009006701A1 Topical medicament |
| 01/15/2009 | WO2009006700A1 Immunology treatment for biofilms |
| 01/15/2009 | WO2008144473A3 Chimeric pufa polyketide synthase systems and uses thereof |
| 01/15/2009 | WO2008121352A3 Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof |
| 01/15/2009 | US20090018809 Computer gene |
| 01/15/2009 | US20090018342 New epothiolone derivatives, process for their production, and their pharmaceutical use |
| 01/15/2009 | US20090018335 Fused heterocyclic compound |
| 01/15/2009 | US20090018331 Condensed imidazole derivatives |
| 01/15/2009 | US20090018314 low affinity receptor for IgE (FceRII/CD23); for modulating or inhibiting induced IgE expression; allergic conditions, autoimmune and inflammatory diseases |
| 01/15/2009 | US20090018208 Novel Succinate Salt of O-Desmethyl-Venlafaxine |
| 01/15/2009 | US20090018181 Drug composition for prevention or inhibition of advance of diabetic complication |
| 01/15/2009 | US20090018177 Propane-1,3-Dione Derivative or Salt Thereof |
| 01/15/2009 | US20090018173 Method for controlling the yeast-to-filamentous growth transition in fungi |
| 01/15/2009 | US20090018164 Farnesyl protein transferase inhibitors for treating breast cancer |
| 01/15/2009 | US20090018143 Thio-substituted arylmethanesulfinyl derivatives |
| 01/15/2009 | US20090018140 Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters |
| 01/15/2009 | US20090018133 Novel Adamantane Derivatives |
| 01/15/2009 | US20090018101 S-adenosyl-l-methionine analogs with extended activated groups for transfer by methyltransferases |
| 01/15/2009 | US20090018077 Fibroblast Growth Factor-Like Polypeptides |
| 01/15/2009 | US20090018076 Fibroblast Growth Factor-Like Polypeptides |
| 01/15/2009 | US20090018073 Administering polypeptide of growth factor to increase mitogenesis; bind to receptors and increase cell differentiation and survival |
| 01/15/2009 | US20090018070 Fsh Mutants |
| 01/15/2009 | US20090018068 G-protein coupled receptors |
| 01/15/2009 | US20090018056 Heteroarylcarbamoylbenzene derivatives |
| 01/15/2009 | US20090018053 Formulations for amylin agonist peptides |
| 01/15/2009 | US20090017534 Nucleotide sequences coding voltage-gated transport proteins for use as screening tools to identify modulators for treatment and prevention of nervous, muscular, glandular, immune, reproductive and epithelial tissue disorders |
| 01/15/2009 | US20090017494 Tick octopamine receptor nucleic acid molecules, proteins and uses thereof |
| 01/15/2009 | US20090017473 Compositions and methods for the diagnosis and treatment of tumor |
| 01/15/2009 | US20090017131 Disinfectant cleaning composition and method |
| 01/15/2009 | US20090017120 Phase stable lecithin organogel composition |
| 01/15/2009 | US20090017090 Devices and methods for delivering active agents to the osteomeatal complex |
| 01/15/2009 | US20090017048 Novel Brachyspira hyodysenteriae vaccine |
| 01/15/2009 | US20090017037 Human TIMP-1 Antibodies |
| 01/15/2009 | US20090017034 inhibits thymic stromal lymphopoietin TSLP)-mediated lymphocyte stimulation; using these polypeptides as molecular weight markers that allow the estimation of the molecular weight of a protein or a fragmented protein |
| 01/15/2009 | US20090017033 Inhibiting receptor activated nuclear factor kappa beta ligand (RANKL); immunoregulation |
| 01/15/2009 | US20090017032 Mammalian cx3c chemokine antibodies |
| 01/15/2009 | US20090017031 Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| 01/15/2009 | US20090017008 Compositions and methods for altering bone density and bone patterning |
| 01/15/2009 | US20090017004 Polymeric drug delivery systems containing an aromatic allylic acid |
| 01/15/2009 | US20090017002 Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes |
| 01/15/2009 | US20090016998 Novel method of prenatal administration of mammalian umbilical cord stem cells for the intrauterine treatment of mammalian lysosomal storage diseases |
| 01/15/2009 | US20090016985 Polymeric drug delivery system containing a multi-substituted aromatic moiety |
| 01/15/2009 | US20090016983 Hair conditioning composition comprising polysaccharide polymer and aminosilicone |
| 01/15/2009 | US20090016965 Internal image antibodies for optical imaging and therapy |
| 01/15/2009 | CA2730009A1 Topical medicament |
| 01/15/2009 | CA2693717A1 Immunology treatment for biofilms |
| 01/15/2009 | CA2692611A1 Di(arylamino)aryl compounds |
| 01/15/2009 | CA2692549A1 Optically active n-(alpha-mercaptopropionyl)glycine |
| 01/14/2009 | EP2014303A2 APO-2L receptor agonist and CPT-11 synergism |
| 01/14/2009 | EP2014297A1 Control of intracellular target molecule by ip3 receptor-binding protein |
| 01/14/2009 | EP2014285A1 NPYY5 antagonists |
| 01/14/2009 | EP2014281A1 Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases. |
| 01/14/2009 | EP2012878A2 Combination therapy for diseases involving angiogenesis |
| 01/14/2009 | EP2012833A2 Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents |
| 01/14/2009 | EP2012831A2 Nanogel contrast agents for optical molecular imaging |
| 01/14/2009 | EP2012791A2 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors |
| 01/14/2009 | EP2012778A2 Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof |
| 01/14/2009 | EP1588707B1 Stable solid medicinal composition for oral administration of ramosetron |
| 01/14/2009 | EP1560584B1 Fab i inhibitors |
| 01/14/2009 | EP1516620B1 Rifampicin for treating angiogenesis |
| 01/14/2009 | EP1477472B1 Substituted phenylalkanoic acid derivative and use thereof |
| 01/14/2009 | EP1463728B1 Fused cyclic modulators of nuclear hormone receptor function |
| 01/14/2009 | EP1443898B1 Product containing a red alga extract of the genus porphyra and uses thereof for protecting cells |
| 01/14/2009 | EP1436291B1 Indolizines as kinase protein inhibitors |
| 01/14/2009 | EP1317443B1 Chemokine receptor binding heterocyclic compounds |
| 01/14/2009 | EP1300396B1 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
| 01/14/2009 | EP1258484B1 Novel isoxazole and thiazole compounds and use thereof as drugs |
| 01/14/2009 | EP1233948B1 Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
| 01/14/2009 | EP1183049B1 Modification of biological elements |
| 01/14/2009 | EP1115877B1 Polynucleotide constructs and uses thereof |
| 01/14/2009 | EP0948539B1 Peptides and compounds that bind to a receptor |
| 01/14/2009 | EP0841937B2 Use of betaglycan to reduce scarring |
| 01/14/2009 | EP0724594B1 Regulation of transcription factor, nf-il6/lap |
| 01/14/2009 | CN101346153A Immunoglobulin G (IGG) concentrate depleted of anti-A and anti-B antibodies and of polyreactive IGGS |
| 01/14/2009 | CN101346149A Ultrasonic cancer treatment enhancer and cell killer |
| 01/14/2009 | CN101343323A Anti-interleukins-8 antibody |